Supreme Court rules that patent reviews detested by pharma are constitutional image

STAT, April 24, 2018
Ed Silverman, quoting Rachel Sachs (Academic Fellow Alumna)


Read the Full Article

From the article:

In a blow to the pharmaceutical industry, the U.S. Supreme Court ruled that a controversial procedure for reviewing patent disputes does not violate the constitutional rights of patent holders.

Known as inter partes reviews, these are heard before a U.S. Patent and Trademark Office appeals board, not a court, and anger drug makers because they are easier and faster to pursue than typical patent lawsuits. Drug companies have argued patents are private property that may be revoked only by a federal court and the review process violates a constitutional right to be heard by a court and jury.

Read more here!

health care finance pharmaceuticals rachel sachs regulation